Demographics of patients treated with and without caplacizumab
| . | Caplacizumab . | Noncaplacizumab . |
|---|---|---|
| Number of patients analyzed | 64 | 50 |
| Male:female (%) | 22:42 (34:66) | 13:37 (26:74) |
| Median age (range), y | 47 (14-78) | 45 (15-89) |
| Ethnicity, n (%) | ||
| Asian | 7 (11) | 9 (18) |
| Black | 26 (41) | 13 (26) |
| White | 31 (48) | 28 (56) |
| De novo:recurrence | 59:5 | 46:4 |
| Mortality, n (%) | 0 | 3 (6) |
| . | Caplacizumab . | Noncaplacizumab . |
|---|---|---|
| Number of patients analyzed | 64 | 50 |
| Male:female (%) | 22:42 (34:66) | 13:37 (26:74) |
| Median age (range), y | 47 (14-78) | 45 (15-89) |
| Ethnicity, n (%) | ||
| Asian | 7 (11) | 9 (18) |
| Black | 26 (41) | 13 (26) |
| White | 31 (48) | 28 (56) |
| De novo:recurrence | 59:5 | 46:4 |
| Mortality, n (%) | 0 | 3 (6) |